Predicting Treatment Response Based on RNA Expression in Large Datasets

PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. While not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets.

https://ift.tt/2FoNt75